ESCMID

Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
목요일, 5월 9, 2024
PFS, FDA, SLATE, Administration, Research, HLA, Death, CRC, Doctor of Philosophy, National Cancer Institute, Vaccine, Development, IND, Melinda French Gates, NCI, AACR, Food, ESCMID, Roche, Messenger, HIV, Therapy, CEPI, Neoplasm, Infection, Gritstone bio, DNA, GMP, Clinical trial, Progression-free survival, Human services, Immunotherapy, Spark Therapeutics, MD, Disease, Patient, Acquisition, VAF, PD, COVID-19, Pharmaceutical industry

-- Gritstone to host conference call today at 4:30pm ET --

Key Points: 
  • In April 2024, Gritstone appointed Stephen Webster to its Board of Directors.
  • Mr. Webster was the Chief Financial Officer of Spark Therapeutics from July 2014 until its acquisition by Roche for $4.3 billion in December 2019.
  • Gritstone expects to share mature PFS data and additional long-term ctDNA data in the third quarter of 2024.
  • In April 2024, Gritstone presented a poster highlighting the durability and potential broad utility of its samRNA COVID-19 vaccine at ESCMID Global 2024.

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

Retrieved on: 
화요일, 5월 7, 2024
Doctor of Philosophy, Infection, EASL, Investment, Safety, NIH, Research, ESCMID, PIPE, SHBG, Part, Therapy, Data, Patient, AASLD, Hepatitis B virus, Hepatology, ETV, CHB, G&A, MBA, Interim, Annual general meeting, SAN, Interest

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the first quarter 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the first quarter 2024.
  • “We have executed on a number of key deliverables to position Aligos for success,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President & CEO of Aligos Therapeutics.
  • “Importantly, we began dosing in the Phase 2a HERALD study of our THR- drug candidate, ALG-055009, and we expect topline data in Q4 2024.
  • In addition, we recently presented data from our three clinical programs at scientific conferences, showcasing our robust pipeline of potentially best-in-class small molecule drug candidates.

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Retrieved on: 
수요일, 5월 8, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Nursing care plan, Investment, IST, Ceftriaxone, New Drug Application, ESCMID, Armata, Acinetobacter, Zoliflodacin, Conference, CNS, Azithromycin, Exercise, Sulbactam, GSK, Patient, Bank, Infection, Gonorrhea, Share repurchase, Growth, Pharmaceutical industry

“Our first quarter financial results continue to demonstrate the successful transformation for Innoviva.

Key Points: 
  • “Our first quarter financial results continue to demonstrate the successful transformation for Innoviva.
  • We are pleased with our first quarter performance, led by the strong launch of our novel therapeutic XACDURO®.
  • Share repurchases: During the first quarter 2024, Innoviva repurchased 0.6 million shares of its outstanding common stock for $9.7 million.
  • In the first quarter 2024, Innoviva invested an additional $35.0 million in one of our assets, Armata, to help advance its lead therapeutic phage candidates.

Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024

Retrieved on: 
금요일, 5월 3, 2024
Infection, Kidney, FDA, Administration, Staphylococcus, ASPR, HHS, SAB, Safety, Ceftobiprole, Methicillin-resistant Staphylococcus aureus, Food, Ceftriaxone, ESCMID, Daptomycin, Partnership, Fungal infection, Development, CABP, TARGET, ABSSSI, Patient, Staphylococcus aureus, Dialysis, Bronchopneumonia, MRSA, Vaccine

Data presented on a third poster demonstrated that bloodstream clearance was achieved at a median of four days after the start of treatment in both the ceftobiprole and comparator groups.

Key Points: 
  • Data presented on a third poster demonstrated that bloodstream clearance was achieved at a median of four days after the start of treatment in both the ceftobiprole and comparator groups.
  • In the group treated with ceftobiprole, fewer patients had Staphylococcus aureus-positive blood cultures after ten days compared to the comparator treatment group.
  • An oral presentation focused on a re-analysis of the previously conducted ceftobiprole phase 3 study in patients with community-acquired bacterial pneumonia (CABP).
  • Using the FDA-CABP-2020 primary endpoint of early clinical success at day 3 after study start, this re-analysis supported the non-inferiority of ceftobiprole to ceftriaxone ± linezolid.

MGI Showcases Life Science Excellence at ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer and New Partnership with ABL Diagnostics

Retrieved on: 
월요일, 4월 29, 2024
Infection, Congress, E25, Genomics, ABL, Laboratory, Health, ESCMID, Software, Business development, ECCMID, Partnership, Research, Workflow, NGS, DNA, DNB, Patient, Microbiology, MGI, Database, HIV, PFI, Exhibition, FASTQ, DNA sequencing, Tuberculosis

During the event taking place from 27-30 April in Barcelona, MGI and ABL Diagnostics (Woippy, France, Euronext: ABLD – ISIN: FR001400AHX6) are pleased to announce its partnership and the compatibility of ABL Diagnostics' DeepChek® assays with MGI's DNBSEQ™ platforms.

Key Points: 
  • During the event taking place from 27-30 April in Barcelona, MGI and ABL Diagnostics (Woippy, France, Euronext: ABLD – ISIN: FR001400AHX6) are pleased to announce its partnership and the compatibility of ABL Diagnostics' DeepChek® assays with MGI's DNBSEQ™ platforms.
  • "Once again, MGI showcases our commitment to supporting healthcare and scientific research and applications across Europe and Africa.
  • We at MGI believe that the power and potential of genomics are boundless," said Dr. Yong Hou, General Manager of MGI Europe and Africa.
  • Moreover, at this year's ESCMID Global 2024, MGI announced a technical assessment of solutions by ABL Diagnostics (ABL), a Euronext-listed company that develops molecular biology assays and software for microbiology genotyping.

Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

Retrieved on: 
금요일, 4월 26, 2024
Infection, ESCMID, Johnson & Johnson, CDTX, DFC, Therapy, Patient, Half-life, SAN, Pharmaceutical industry

The first presentation highlights data from the Phase 2a study of CD388, showing the DFC was well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challenged with influenza.

Key Points: 
  • The first presentation highlights data from the Phase 2a study of CD388, showing the DFC was well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challenged with influenza.
  • The second presentation highlights data from a Phase 1 single ascending dose study of CD388 which showed the drug has an extended half-life of 6-8 weeks.
  • These data underscore the potential of CD388 to provide patients with seasonal influenza prevention.
  • “Data presentations at the ESCMID 2024 conference support our belief that CD388 has the potential to provide season-long, universal protection from influenza,” said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara.

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Retrieved on: 
목요일, 4월 25, 2024
Doctor of Philosophy, Infection, Safety, Pandemic, Pharmacokinetics, ESCMID, Science, Therapy, Liver, MBA, Government, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona, Spain.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona, Spain.
  • The presentation highlights ALG-097558 Phase 1 data showing that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy volunteers with a PK profile supporting twice daily ritonavir-free dosing without a food effect.
  • “We are pleased to present these ALG-097558 data, which further highlight the best-in-class potential of this pan-coronavirus protease inhibitor and its substantial differentiation versus current standard of care coronavirus antiviral drugs like nirmatrelvir/ritonavir (PAXLOVIDTM),” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “These data further demonstrate that Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates.

deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024

Retrieved on: 
목요일, 4월 25, 2024
Septic, Mortality, Laboratory, Sepsis, Risk, Hospital, Blood, Infection, ESCMID, Septic shock, Research, PCR, Patient, Fungus, Diagnosis, Medical device

UllCORE is a benchtop diagnostic system designed to deliver 50 reportable results in one hour covering 95% of sepsis-causing pathogens and resistance genes.

Key Points: 
  • UllCORE is a benchtop diagnostic system designed to deliver 50 reportable results in one hour covering 95% of sepsis-causing pathogens and resistance genes.
  • The real-time multiplex PCR system extracts total microbial DNA from 8 mL of whole blood, circumventing the lengthy blood culture process.
  • Beyond sepsis, deepull believes its system has the potential to be applicable to a wide range of acute infections.
  • The product will be debuted at this year’s ESCMID Global 2024 conference, taking place in Barcelona from 27-30 April.

QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance

Retrieved on: 
수요일, 4월 24, 2024
TST, Genetically modified bacteria, WHO, Virtual reality, CDC, Multidrug-resistant tuberculosis, Bacteria, AMR, ESCMID, QIAGEN, ECCMID, MDR-TB, WGS, Doctor of Philosophy, Research, Workflow, Sputum, NGS, PCR, Disease, Patient, Panel, Mycobacterium tuberculosis, QGEN, Gold, Infection, D20, Emerging, Tuberculosis, Cerebrospinal fluid, Vaccine

The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).

Key Points: 
  • The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).
  • By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
  • “The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance,” said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN.
  • The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment.

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024

Retrieved on: 
목요일, 4월 18, 2024
Infection, University of Southern California, Medical microbiology, University, Mycobacteroides abscessus, Tuberculosis, Epidemiology, ESCMID, ECCMID, Erasmus MC, Urinary tract infection, Science, MAC, Antimycobacterial, Mycobacterium avium complex, Clinical pharmacy, Immunity, TB, National Jewish Health, Division, Pharmaceutical industry

BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).

Key Points: 
  • BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).
  • The hybrid conference will be held April 27-30 at the Fira Gran Via in Barcelona, Spain.
  • “Paratek continues to invest in science to further our understanding of NUZYRA, as well as explore its future utility in addressing additional unmet patient needs,” said Randy Brenner, chief development and regulatory officer of Paratek.
  • “Next week’s ESCMID presentations include a study assessing the potential immunomodulating properties of NUZYRA in addition to its antibacterial activity.